ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Fundamental Analysis & Valuation

NASDAQ:ZYBT • KYG989MS1016

0.809 USD
+0.04 (+5.06%)
Last: Mar 4, 2026, 08:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ZYBT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ZYBT. ZYBT was compared to 193 industry peers in the Pharmaceuticals industry. ZYBT has a bad profitability rating. Also its financial health evaluation is rather negative. ZYBT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. ZYBT Profitability Analysis

1.1 Basic Checks

  • In the past year ZYBT has reported negative net income.
  • In the past year ZYBT had a positive cash flow from operations.
ZYBT Yearly Net Income VS EBIT VS OCF VS FCFZYBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M 40M 60M

1.2 Ratios

  • The Return On Assets of ZYBT (-2.05%) is better than 75.65% of its industry peers.
  • With a decent Return On Equity value of -3.46%, ZYBT is doing good in the industry, outperforming 78.76% of the companies in the same industry.
Industry RankSector Rank
ROA -2.05%
ROE -3.46%
ROIC N/A
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZYBT Yearly ROA, ROE, ROICZYBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 5 10 15

1.3 Margins

  • In the last couple of years the Profit Margin of ZYBT has declined.
  • In the last couple of years the Operating Margin of ZYBT has declined.
  • ZYBT's Gross Margin of 44.51% is fine compared to the rest of the industry. ZYBT outperforms 64.25% of its industry peers.
  • ZYBT's Gross Margin has declined in the last couple of years.
  • ZYBT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.51%
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
ZYBT Yearly Profit, Operating, Gross MarginsZYBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ZYBT Health Analysis

2.1 Basic Checks

  • ZYBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ZYBT remains at a similar level compared to 1 year ago.
  • The debt/assets ratio for ZYBT has been reduced compared to a year ago.
ZYBT Yearly Shares OutstandingZYBT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
ZYBT Yearly Total Debt VS Total AssetsZYBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • ZYBT has an Altman-Z score of 1.47. This is a bad value and indicates that ZYBT is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.47, ZYBT is in the better half of the industry, outperforming 60.62% of the companies in the same industry.
  • ZYBT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • ZYBT has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 1.47
ROIC/WACCN/A
WACC7.22%
ZYBT Yearly LT Debt VS Equity VS FCFZYBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • ZYBT has a Current Ratio of 1.49. This is a normal value and indicates that ZYBT is financially healthy and should not expect problems in meeting its short term obligations.
  • ZYBT has a Current ratio of 1.49. This is in the lower half of the industry: ZYBT underperforms 70.47% of its industry peers.
  • A Quick Ratio of 1.10 indicates that ZYBT should not have too much problems paying its short term obligations.
  • The Quick ratio of ZYBT (1.10) is worse than 75.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 1.1
ZYBT Yearly Current Assets VS Current LiabilitesZYBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ZYBT Growth Analysis

3.1 Past

  • ZYBT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -123.72%.
  • Measured over the past years, ZYBT shows a very strong growth in Earnings Per Share. The EPS has been growing by 528.02% on average per year.
  • Looking at the last year, ZYBT shows a very negative growth in Revenue. The Revenue has decreased by -18.89% in the last year.
  • The Revenue has been growing by 854.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-123.72%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-332.08%
Revenue 1Y (TTM)-18.89%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-34.36%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYBT Yearly Revenue VS EstimatesZYBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

Find the best growth stocksShow best growing peers

1

4. ZYBT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZYBT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYBT Price Earnings VS Forward Price EarningsZYBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ZYBT is valued a bit cheaper than the industry average as 79.79% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 22.69
ZYBT Per share dataZYBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZYBT Dividend Analysis

5.1 Amount

  • ZYBT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZYBT Fundamentals: All Metrics, Ratios and Statistics

ZHENGYE BIOTECHNOLOGY HOLDIN

NASDAQ:ZYBT (3/4/2026, 8:02:40 PM)

0.809

+0.04 (+5.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.33%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap38.34M
Revenue(TTM)248.68M
Net Income(TTM)-10.36M
AnalystsN/A
Price TargetN/A
Short Float %0.55%
Short Ratio1.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP-1.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.06
P/FCF N/A
P/OCF 21.38
P/B 0.89
P/tB 0.96
EV/EBITDA 22.69
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0.04
OCFY4.68%
SpS0.76
BVpS0.91
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.05%
ROE -3.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.51%
FCFM N/A
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.37
Cap/Depr 50.15%
Cap/Sales 5.07%
Interest Coverage N/A
Cash Conversion 97.56%
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 1.1
Altman-Z 1.47
F-Score3
WACC7.22%
ROIC/WACCN/A
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-123.72%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-332.08%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.89%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-34.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-119.24%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A

ZHENGYE BIOTECHNOLOGY HOLDIN / ZYBT FAQ

What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZYBT.


What is the valuation status of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

ChartMill assigns a valuation rating of 1 / 10 to ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT). This can be considered as Overvalued.


Can you provide the profitability details for ZHENGYE BIOTECHNOLOGY HOLDIN?

ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a profitability rating of 2 / 10.


What is the financial health of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

The financial health rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 3 / 10.